New York Times Co (NYT) Stock Price Today
Aura AI Summary
Key Stats
- $11.33BMARKET_CAP
- -VOLUME
- MediaSECTOR
- $85.86FIFTY_TWO_WEEK_HIGH
- $51.43FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $10.72BENTERPRISE_VALUE
- 1.25%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track New York Times Co (NYT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, New York Times Co has traded between a low of $51.43 and a high of $85.86, highlighting its annual price range. Buy and sell New York Times Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Most Recent News
Global beadlets capsule market to nearly double to $968M by 2035 with 6.85% CAGR driven by pharma and nutraceutical demand
The global beadlets capsule market is projected to grow from $467.26 million in 2025 to $968.45 million by 2035, at a compound annual growth rate of 6.85%. Growth is driven by rising demand in pharmaceutical and nutraceutical sectors, fueled by advan...

China's oil imports drop amid Middle East conflict and OPEC+ supply boost
China, the world's largest crude oil importer, has significantly reduced its oil purchases, including from Iran, amid the ongoing Middle East conflict and a strategic shift towards green energy. In May, China's crude imports fell 29% year-on-year to ...

Molecular Partners advances phase 1/2a trial of cancer-targeting Radio-DARPin MP0712 with initial data due soon
Molecular Partners is progressing its Phase 1/2a clinical trial of MP0712, a Radio-DARPin therapeutic targeting DLL3 for small cell lung and neuroendocrine cancers, with patient dosing ongoing at five US centers. Initial clinical data are expected wi...
